- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00985244
Macrolide Maintenance Therapy in Chronic Obstructive Pulmonary Disease (COLUMBUS)
Influence of Macrolide Maintenance Therapy and Bacterial Colonisation on Exacerbation Frequency and Progression of COPD, a Randomized Double-blind Placebo-controlled Trial
연구 개요
상세 설명
COPD is characterized by progressive development of airflow limitation that is poorly reversible. Because of a poor understanding of COPD pathogenesis, treatment is mostly symptomatic and new therapeutic strategies are limited. There is a direct relationship between the severity of the disease and the intensity of the inflammatory response.One of the hypothesis for persistent airway inflammation is that the presence of recurrent infections is responsible for this condition.
Macrolide antibiotics have a bacteriostatic as well as anti-inflammatory properties. This clinical trial will investigate whether maintenance treatment with macrolide antibiotics during 1 year in people with 3 or more exacerbations in the preceding year of inclusion can decrease the exacerbation rate in that same year of treatment.
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Noord-Brabant
-
Breda, Noord-Brabant, 네덜란드, 4818 CK
- Amphia Ziekenhuis
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Diagnosis of COPD according to GOLD criteria (FEV1/FVC<70%), classification into GOLD I (FEV1 70-100% predicted), GOLD II (FEV1 50-70% predicted), GOLD III (FEV1 30- 50% predicted) or GOLD IV (FEV1 ≤ 30% predicted)
- Age ≥ 18 years
- Three or more exacerbations of COPD in one year for which a course of prednisone and/or antibiotic therapy was started
- Clinically stable during 1 month. Patients have to be free of COPD exacerbation or respiratory tract infection within a month prior to involvement in the study and they should not have received a high dose of systemic glucocorticoids or antibiotics in this period
- Informed consent
Exclusion Criteria:
- Use of antibiotics or high dose of systemic steroids within a month prior to involvement in the study.
- Addition of inhalation steroids to the patient's therapy regimen, shortly before entering the study.
- Pregnant or lactating women.
- Allergy to macrolides.
- Liver disease (alanine transaminase and/or aspartate transaminase levels 2 or more times the upper limit of normal).
- Asthma, defined as episodic symptoms of airflow obstruction which is reversible with bronchodilators, assessed with lung function testing.
- Presence of a malignancy which is clinically active.
- Bronchiectasis.
- Malignancy of any kind for which the subject is under treatment or is being monitored as part of follow up after treatment.
- Heart failure.
- Use of drugs which can adversely interact with macrolides and for which therapeutic monitoring cannot be undertaken.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
활성 비교기: Azithromycin
Subjects in this group will receive 3 times a week 500 mg of the antibiotic azithromycin
|
Subjects in this group will receive 3 times a week 500 mg of the antibiotic azithromycin during 1 year.
다른 이름들:
|
위약 비교기: Placebo
Subjects in this group will receive 3 times a week placebo
|
Persons in this group will receive 3 times a week placebo of azithromycin during 1 year.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
Reduction in number of exacerbations
기간: 1 year
|
1 year
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Lung function parameters (FEV1 (L), FVC (L), FRC (L), RV (L), TLC(L), IC (L), 6 minute walking distance)
기간: Day 1. Also 3, 6, 9 and 12 months.
|
Day 1. Also 3, 6, 9 and 12 months.
|
|
Disease specific health related quality of life measured by St. George's Respiratory Questionnaire (SGRQ)
기간: Day 1. Also 3, 6, 9 and 12 months. In case of an exacerbation.
|
Day 1. Also 3, 6, 9 and 12 months. In case of an exacerbation.
|
|
Indication of anxiety and depression by Hospital Anxiety Depression Scale (HADS)
기간: Day 1. Also 3, 6, 9 and 12 months.
|
Day 1. Also 3, 6, 9 and 12 months.
|
|
Microbiology of sputum (culture and PCR).
기간: Day 1. Also 3, 6, 9 and 12 months. In case of an exacerbation of COPD.
|
Day 1. Also 3, 6, 9 and 12 months. In case of an exacerbation of COPD.
|
|
Measurement of inflammatory markers in sputum and serum.
기간: Day 1. Also 3, 6, 9 and 12 months. In case of an exacerbation of COPD.
|
Day 1. Also 3, 6, 9 and 12 months. In case of an exacerbation of COPD.
|
|
Adverse events of treatment.
기간: Day 1. Also 3, 6, 9 and 12 months. Whenever adverse events occur.
|
Day 1. Also 3, 6, 9 and 12 months. Whenever adverse events occur.
|
|
Length of hospital stay.
기간: Whenever admission to hospital is required for an exacerbation of COPD.
|
Whenever admission to hospital is required for an exacerbation of COPD.
|
|
Time till next exacerbation.
기간: Whenever an exacerbation of COPD occurs.
|
Whenever an exacerbation of COPD occurs.
|
|
Assess type D personality by DS-14 questionnaire.
기간: Day 1 and month 12.
|
Day 1 and month 12.
|
|
Generic health status measured by 12-Item Short Form Health Survey (SF-12).
기간: Day 1, month 3, 6, 9 and 12. In case of an exacerbation.
|
Day 1, month 3, 6, 9 and 12. In case of an exacerbation.
|
|
Decrease in percentage of clinical versus outdoor department exacerbations.
기간: Month 12.
|
Month 12.
|
|
Effect of maintenance macrolides on intestinal bacterial restistancy patterns
기간: Day 1, month 6 and month 12
|
Day 1, month 6 and month 12
|
|
Serology and PCR for atypical microorganisms in serum
기간: day 1. In case of an exacerbation.
|
day 1. In case of an exacerbation.
|
|
Intestinal bacterial resistance patterns
기간: Day 1, month 6 and month 12
|
Rectal swabs will be tested for bacterial resistance patterns and change in rectal flora as a result of maintenance azithromycin.
|
Day 1, month 6 and month 12
|
공동 작업자 및 조사자
스폰서
수사관
- 연구 책임자: Joachim Aerts, MD, PhD, Amphia Ziekenhuis
- 연구 책임자: Menno van der Eerdem, MD, PhD, Erasmus Medical Center
간행물 및 유용한 링크
일반 간행물
- Djamin RS, Talman S, Schrauwen EJA, von Wintersdorff CJH, Wolffs PF, Savelkoul PHM, Uzun S, Kerstens R, van der Eerden MM, Kluytmans JAJW. Prevalence and abundance of selected genes conferring macrolide resistance genes in COPD patients during maintenance treatment with azithromycin. Antimicrob Resist Infect Control. 2020 Jul 28;9(1):116. doi: 10.1186/s13756-020-00783-w.
- Uzun S, Djamin RS, Kluytmans JA, Mulder PG, van't Veer NE, Ermens AA, Pelle AJ, Hoogsteden HC, Aerts JG, van der Eerden MM. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014 May;2(5):361-8. doi: 10.1016/S2213-2600(14)70019-0. Epub 2014 Apr 15.
- Uzun S, Djamin RS, Kluytmans J, Van't Veer NE, Ermens AA, Pelle AJ, Mulder P, van der Eerden MM, Aerts J. Influence of macrolide maintenance therapy and bacterial colonisation on exacerbation frequency and progression of COPD (COLUMBUS): study protocol for a randomised controlled trial. Trials. 2012 Jun 9;13:82. doi: 10.1186/1745-6215-13-82.
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- Amphia-ABR29500
- 2009-015857-19 (EudraCT 번호)
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
COPD에 대한 임상 시험
-
Istituto Nazionale di Ricovero e Cura per Anziani모병
-
Bio-Sensing Solutions S.L. (DyCare)Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau; Centre de Validació...모병
-
The First Affiliated Hospital of Guangzhou Medical...모병
-
Association des Réseaux BronchioliteLaboratoire Système et Matériaux pour la Mécatronique (SYMME)모병
-
Polytechnic Institute of PortoNippon Gases Portugal모병
Azithromycin에 대한 임상 시험
-
Brigham and Women's HospitalBill and Melinda Gates Foundation아직 모집하지 않음감염성 질병 | 약물 효과 | 임상 감염
-
Copenhagen Studies on Asthma in Childhood모병
-
Woman's모병조산 | 조산 | 막파열; 조기 | 막파열; 분만 지연(자발 파열 후) | 막파열; 조산, 태아에 영향 | 조기 PROM(임신)미국
-
VA Office of Research and DevelopmentNational Heart, Lung, and Blood Institute (NHLBI); Northwestern University Feinberg School...종료됨
-
University of MinnesotaNational Heart, Lung, and Blood Institute (NHLBI)완전한
-
University Hospital, Strasbourg, France빼는Sars-CoV-2, 지역사회획득폐렴,COVID-19
-
Tehran University of Medical Sciences완전한